Today’s Research Reports on Stocks to Watch: OPKO Health and Bellicum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 10, 2018 / Both OPKO Health and Bellicum Pharmaceuticals were flying high in the green on Wednesday after announcing first quarter results. Traders were enthusiastic over OPKO's Rayladee performance in the first quarter.
RDI Initiates Coverage on:
OPKO Health, Inc.
https://rdinvesting.com/news/?ticker=OPK
Bellicum Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=BLCM
OPKO Health, Inc. shares closed up a little over 29% on Wednesday with roughly 16 million shares traded. For the first quarter ended March 31, 2018, the company saw a net loss of $43.1 million and ended up with just $99.9 million in cash and cash equivalents. This didn't faze investors as the multinational pharma and diagnostics company reported better than expected first quarter earnings results with a revenue beat of $18 million. OPKO reported consolidated revenues of $254.9 million. This was however a decline compared with $266.4 million for the comparable quarter of 2017. The company also announced that the commercial launches of its drug Rayaldee for chronic kidney disease, as well as its prostate cancer test 4K score, were beginning to gain momentum. Rayaldee total prescriptions reported by IMS for the first quarter saw an increase of 730% compared to the first quarter of 2017. The company's 4K score utilization in the first quarter also saw a 13% increase compared to the year ago quarter.
Access RDI's OPKO Health, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OPK
Bellicum Pharmaceuticals, Inc. shares closed up 15.60% yesterday on about 1.9 million shares traded. It was on Tuesday that the leader in developing novel, controllable cellular immunotherapies for cancers as well as orphan inherited blood disorders, announced its first quarter 2018 results and highlights of its programs. Since this is a pre-revenue development stage company, it did not have much to report on the income statement side. The management believes it has a comfortable cash position to take care of its operating expenses till the end of 2019. The company shared update on a long list of ongoing clinical trials and everything was on track for its top drug candidate to deliver top-line data by the end of 2018 and go up for regulatory review in Europe sometime in 2019. CEO Rick Fair said, "We remain very encouraged with interim results from our BPX-501 program in malignant and nonmalignant pediatric patients, and remain on track for filing of MAAs in the European Union in 2019. We are also working to expand the BPX-501 opportunity into the U.S. and into the adult stem cell transplant population with the planned initiation of two new clinical trials later this year. In our BPX-601 GoCAR-T program, we reported early promising first-in-human data on CAR-T cell expansion with the use of our iMC activation switch. We look forward to sharing data readouts on all our clinical programs during 2018, and providing further guidance on our plans to advance two new dual-switch controllable CAR-T candidates into clinical studies."
Access RDI's Bellicum Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLCM
Our Actionable Research on OPKO Health, Inc. (NASDAQ: OPK) and Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
